Electromed Inc. (ELMD)
ELMD trades on NYSE in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1488917/000143774926028914/0001437749-26-028914-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | ELMD on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2011 |
| SEC CIK | 0001488917 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | MN |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $73.8M |
| Net income | $11.3M |
| Operating income | $13.9M |
| Net margin | 15.3% |
| Operating margin | 18.8% |
| Revenue growth | +15.3% |
| Cash | $20.4M |
| Total assets | $66.3M |
| P/E (computed) | 16.7× |
| P/S (computed) | 2.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $15.9M cash; operating cash flow $2.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 8,174,008 (2026-11-03); 8,340,538 a year earlier; 8,581,677 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Minneapolis, Minnesota, United States | PCAOB Form AP 2026-09-15 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $18.7M | $2.8M | $373K | $15.9M | No debt tags | $75.6M | 10-Q 2026-11-10 |
| Q4 2026 2026-06-30 | $19.4M | $3.4M | $3.0M | $20.4M | No debt tags | $73.8M | 10-K 2026-08-25 |
| Q3 2026 2026-03-31 | $18.6M | $3.0M | $3.5M | $17.0M | No debt tags | $71.8M | 10-Q 2026-05-12 |
| Q2 2026 2025-12-31 | $18.9M | $2.8M | $3.0M | $13.8M | No debt tags | $68.9M | 10-Q 2026-02-10 |
| Q1 2026 2025-09-30 | $16.9M | $2.1M | $169K | $14.1M | No debt tags | $66.2M | 10-Q 2026-11-10 |
| Q4 2025 2025-06-30 | $17.4M | $2.2M | $3.9M | $15.3M | No debt tags | $64.0M | 10-K 2026-08-25 |
| Q3 2025 2025-03-31 | $15.7M | $1.9M | $2.1M | $15.2M | No debt tags | $61.4M | 10-Q 2026-05-12 |
| Q2 2025 2024-12-31 | $16.3M | $2.0M | $3.2M | $16.2M | No debt tags | $59.6M | 10-Q 2025-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424(B)(4) | 424B4 | 2010-08-13 |
| Latest annual report FORM 10-K | 10-K | 2026-08-25 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-09-29 |
Source: SEC EDGAR submissions feed, 582 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.5% |
| 1 month | -12.1% |
| 3 months | -42.8% |
| Year to date | -16.5% |
| 1 year | -7.7% |
| From 52-week high | -47.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier